Top

Published in:

01-02-2009 | Original Article

Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy

Authors: Roberto Sciagrà, MD, Barbara Sotgia, MD, Iacopo Olivotto, MD, Franco Cecchi, MD, Stefano Nistri, MD, Paolo G. Camici, MD, FACC, FESC, FAHA, FRCP, Alberto Pupi, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2009

Abstract

Background

Atrial fibrillation (AF) and coronary microvascular dysfunction (CMD) are common in hypertrophic cardiomyopathy (HCM), but whether they are associated is unclear. We assessed the relationship between AF and CMD in HCM.

Methods and Results

Global hyperemic myocardial blood flow (hMBF) was measured in 95 HCM patients (16 with, 79 without paroxysmal or chronic AF) by N-13 ammonia positron emission tomography (PET) after dipyridamole infusion. AF patients were older (50.5 ± 13.4 vs. 38.7 ± 14.9 years, P < .0005), had larger left atrial diameter (49.8 ± 7.4 vs 38.6 ± 5.7 mm, P < .00001), and left ventricular end-systolic diameter (30.4 ± 6.7 vs 25.5 ± 5.3 mm, P < .005) compared with those in stable sinus rhythm. In patients with AF, hMBF was significantly lower (1.23 ± 0.44 vs 1.87 ± 0.90 mL/min/g, P < 0.0001). In multivariate logistic regression analysis, hMBF, left atrial diameter, and age were independently associated with AF (P < .05 for all).

Conclusions

HCM patients with paroxysmal or chronic AF have lower hMBF than those in stable sinus rhythm. The association between CMD and AF is independent of other known predictors of AF, suggesting a causal link between these two features.

Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002;287:1308-20.PubMedCrossRef

Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24.PubMedCrossRef

Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D’Alessandro G, et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895-900.PubMedCrossRef

Camici PG, Chiriatti G, Lorenzoni R, Bellina CR, Gistri R, Italiani G, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: A study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-86.PubMed

Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40.PubMedCrossRef

Lorenzoni R, Gistri R, Cecchi F, Olivotto I, Chiriatti G, Elliott P, et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am Heart J 1998;136:972-81.PubMedCrossRef

Choudhury L, Elliott P, Rimoldi O, Ryan M, Lammertsma AA, Boyd H, et al. Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 1999;94:49-59.PubMedCrossRef

Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.PubMedCrossRef

Olivotto I, Cecchi F, Gistri R, Lorenzoni R, Chiriatti G, Girolami F, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:1043-8.PubMedCrossRef

10.

Bellina CR, Parodi O, Camici PG, Salvadori PA, Taddei L, Fusani L, et al. Simultaneous in vitro and in vivo validation of ¹³N-Ammonia for the assessment of regional myocardial blood flow. J Nucl Med 1990;31:1335-43.PubMed

11.

Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15:1032-42.PubMedCrossRef

12.

Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, et al. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Circulation 1997;95:1686-744.PubMed

13.

Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation 2005;111:2033-41.PubMedCrossRef

14.

Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98:960-5.PubMedCrossRef

15.

Olivotto I, Maron BJ, Cecchi F. Pathophysiology and clinical consequences of atrial fibrillation in hypertrophic cardiomyopathy. In: Maron BJ, editor. Diagnosis and management of hypertrophic cardiomyopathy. Cambridge, MA: Blackwell Futura; 2004. p. 105-20.CrossRef

16.

Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-82.PubMedCrossRef

17.

Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988-98.PubMedCrossRef

18.

Mehta RH, Dabbous OH, Granger CB, Kuznetsova P, Kline-Rogers EM, Anderson FA Jr, et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 2003;92:1031-6.PubMedCrossRef

19.

Pedersen OD, Abildstrøm SZ, Ottesen MM, Rask-Madsen C, Bagger H, Køber L, et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J 2006;27:290-5.PubMedCrossRef

20.

Bunch TJ, Chandrasekaran K, Ehrsam JE, Hammill SC, Urban LH, Hodge DO, et al. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy. Am J Cardiol 2007;99:835-8.PubMedCrossRef

21.

Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-2.PubMedCrossRef

Title: Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy
Authors: Roberto Sciagrà, MD
Barbara Sotgia, MD
Iacopo Olivotto, MD
Franco Cecchi, MD
Stefano Nistri, MD
Paolo G. Camici, MD, FACC, FESC, FAHA, FRCP
Alberto Pupi, MD
Publication date: 01-02-2009
Publisher: Springer-Verlag
Published in: Journal of Nuclear Cardiology / Issue 1/2009
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-008-9005-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy

Abstract

Background

Methods and Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Incremental prognostic value of cardiac single-photon emission computed tomography after nitrate administration in patients with ischemic left ventricular dysfunction

A time to focus on patient outcomes

The WOMEN study: What is the optimal method for ischemia evaluation in women? A multi-center, prospective, randomized study to establish the optimal method for detection of coronary artery disease (CAD) risk in women at an intermediate-high pretest likelihood of CAD: study design

Intra-patient reproducibility of myocardial SPECT imaging with 201Tl

Endothelial dysfunction: the reversible coronary disease

The additive prognostic value of perfusion and functional data assessed by quantitative gated SPECT in women